US 7,589,073 B2
	Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
John L. Diener, Cambridge, Mass. (US); H. A. Daniel Lagassé, Somerville, Mass. (US); and Claude Benedict, Cambridge, Mass. (US)
Assigned to Archemix Corp., Cambridge, Mass. (US)
Filed on Jan. 12, 2006, as Appl. No. 11/332,729.
Application 11/332729 is a continuation of application No. 11/222346, filed on Sep. 07, 2005.
Claims priority of provisional application 60/608047, filed on Sep. 07, 2004.
Claims priority of provisional application 60/661950, filed on Mar. 11, 2005.
Claims priority of provisional application 60/678427, filed on May 06, 2005.
Claims priority of provisional application 60/690231, filed on Jun. 13, 2005.
Prior Publication US 2006/0264369 A1, Nov. 23, 2006
This patent is subject to a terminal disclaimer.
Int. Cl. A01N 43/04 (2006.01); C12Q 1/68 (2006.01); C12P 19/34 (2006.01); C07H 21/02 (2006.01)

U.S. Cl. 514—44  [435/6; 435/91.1; 435/375; 536/23.1]

40 Claims

1. An aptamer that binds to a von Willebrand Factor target, wherein the aptamer modulates von Willebrand Factor-mediated platelet adhesion, activation and/or aggregation and the aptamer is SEQ ID NO: 291 (ARC1368), and wherein the aptamer comprises a KD for von Willebrand Factor of less than 100 nM.